Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
gene therapy |
| gptkbp:administeredBy |
adults
single infusion |
| gptkbp:antigen |
gptkb:B-cell_maturation_antigen
|
| gptkbp:approvalYear |
2022-02-28
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_States gptkb:FDA multiple myeloma |
| gptkbp:ATCCode |
L01XL10
|
| gptkbp:blackBoxWarning |
cytokine release syndrome
neurologic toxicities |
| gptkbp:brand |
gptkb:Carvykti
|
| gptkbp:developedBy |
gptkb:Legend_Biotech
gptkb:Janssen_Pharmaceuticals |
| https://www.w3.org/2000/01/rdf-schema#label |
relmacabtagene autoleucel
|
| gptkbp:indication |
relapsed or refractory multiple myeloma
|
| gptkbp:mechanismOfAction |
targets BCMA
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
infections
neurotoxicity cytokine release syndrome hematologic toxicity |
| gptkbp:storage |
cryopreserved
|
| gptkbp:treatment |
autologous cell therapy
|
| gptkbp:bfsParent |
gptkb:JW_Therapeutics
|
| gptkbp:bfsLayer |
7
|